Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...
-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly synergistic with...
Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...
New data reinforce Mirum’s commitment to advancing therapies and improving the lives of patients across diverse rare liver diseases.
- Third quarter 2025 total revenue of $133 million - 2025 revenue guidance updated to $500 to $510 million - Phase 2b VISTAS topline data expected second quarter of 2026 - Conference...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...